RU2653756C2 - Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 - Google Patents

Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 Download PDF

Info

Publication number
RU2653756C2
RU2653756C2 RU2014135703A RU2014135703A RU2653756C2 RU 2653756 C2 RU2653756 C2 RU 2653756C2 RU 2014135703 A RU2014135703 A RU 2014135703A RU 2014135703 A RU2014135703 A RU 2014135703A RU 2653756 C2 RU2653756 C2 RU 2653756C2
Authority
RU
Russia
Prior art keywords
seq
influenza virus
amino acid
polypeptide
virus
Prior art date
Application number
RU2014135703A
Other languages
English (en)
Russian (ru)
Other versions
RU2014135703A (ru
Inventor
Тед М. РОСС
Дональд М. КАРТЕР
Кори Дж. КРЕВАР
Original Assignee
Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн filed Critical Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн
Publication of RU2014135703A publication Critical patent/RU2014135703A/ru
Application granted granted Critical
Publication of RU2653756C2 publication Critical patent/RU2653756C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2014135703A 2012-02-07 2013-02-06 Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 RU2653756C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596014P 2012-02-07 2012-02-07
US61/596,014 2012-02-07
PCT/US2013/024957 WO2013119683A1 (en) 2012-02-07 2013-02-06 Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018113521A Division RU2018113521A (ru) 2012-02-07 2013-02-06 Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b

Publications (2)

Publication Number Publication Date
RU2014135703A RU2014135703A (ru) 2016-03-27
RU2653756C2 true RU2653756C2 (ru) 2018-05-14

Family

ID=48947966

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014135703A RU2653756C2 (ru) 2012-02-07 2013-02-06 Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
RU2018113521A RU2018113521A (ru) 2012-02-07 2013-02-06 Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018113521A RU2018113521A (ru) 2012-02-07 2013-02-06 Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b

Country Status (14)

Country Link
US (1) US9234008B2 (enExample)
EP (1) EP2812348A4 (enExample)
JP (1) JP6336915B2 (enExample)
KR (1) KR20140127827A (enExample)
CN (1) CN104136456A (enExample)
AU (2) AU2013217166B2 (enExample)
BR (1) BR112014018884A2 (enExample)
CA (1) CA2863981A1 (enExample)
HK (1) HK1203524A1 (enExample)
IN (1) IN2014DN05805A (enExample)
MX (1) MX2014009148A (enExample)
RU (2) RU2653756C2 (enExample)
SG (1) SG11201404653UA (enExample)
WO (1) WO2013119683A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809237C2 (ru) * 2018-06-27 2023-12-08 Медикаго Инк. Мутанты гемагглютинина вируса гриппа

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011302360B2 (en) * 2010-09-14 2015-01-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
JP6175452B2 (ja) 2012-02-13 2017-08-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ヒトおよびトリｈ５ｎ１インフルエンザのための、計算で最適化した反応性の広い抗原
BR112014023900A2 (pt) 2012-03-30 2020-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polipeptídeo de hemaglutimina de influenza recombinante, molécula de ácido nucleicoisolada, vetor, célula isolada, partícula semelhante ao vírus da influenza, proteína de fusão, composição, e uso
AU2013352179B2 (en) 2012-11-27 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
CN107847579A (zh) * 2014-12-19 2018-03-27 俄勒冈健康与科学大学 人和禽h5n1流感的计算优化的广泛反应性抗原的协同共同给药
US10584148B2 (en) 2015-06-02 2020-03-10 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
EP3307761A4 (en) 2015-06-09 2019-01-16 Sanofi Pasteur Inc. PROCESS FOR OPTIMIZING NUCLEOTIDE SEQUENCES COPING MANIPULATED INFLUENZA PROTEINS
US10485864B2 (en) 2015-09-21 2019-11-26 Oregon Health & Science University Characterization of influenza vaccines
MA45165A (fr) 2016-06-02 2019-04-10 Sanofi Pasteur Inc Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées
CA3026094A1 (en) 2016-06-03 2017-12-07 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
US20210225457A1 (en) * 2018-07-13 2021-07-22 University Of Georgia Research Foundation Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof
CN113453710A (zh) * 2018-09-28 2021-09-28 剑桥大学的校长、教师和学者 疫苗和方法
WO2024167855A1 (en) * 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU97121580A (ru) * 1995-05-26 1999-10-27 Эм Джи-Пи эм Си, Л.Л.Си. Способ получения гемагглютининовых поливалентных вакцин против гриппа
US7459162B2 (en) * 2003-06-16 2008-12-02 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2008145129A2 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
EP2307549A1 (en) * 2008-07-11 2011-04-13 Medicago Inc. Influenza virus-like particles (vlps) comprising hemagglutinin
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
US20110182938A1 (en) * 2010-01-26 2011-07-28 Weiner David B Influenza nucleic acid molecules and vaccines made therefrom

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
CN1311871C (zh) 2000-03-02 2007-04-25 爱莫里大学 Dna表达载体及其应用方法
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
CA2633793A1 (en) 2005-12-19 2007-06-28 Novartis Vaccines And Diagnostics S.R.L. Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
JP2009537147A (ja) * 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
US8980281B2 (en) 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2061887B1 (en) 2006-10-04 2018-01-24 The University Of Queensland Vlp based influenza vaccine delivery system
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
CN101877965B (zh) 2007-11-12 2014-08-20 宾夕法尼亚大学托管会 针对流感病毒的多种亚型的疫苗
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
JP5797636B2 (ja) 2009-04-03 2015-10-21 メリアル リミテッド ニューカッスル病ウイルスをベクターとするトリワクチン
AU2011302360B2 (en) 2010-09-14 2015-01-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU97121580A (ru) * 1995-05-26 1999-10-27 Эм Джи-Пи эм Си, Л.Л.Си. Способ получения гемагглютининовых поливалентных вакцин против гриппа
US7459162B2 (en) * 2003-06-16 2008-12-02 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2008145129A2 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
EP2307549A1 (en) * 2008-07-11 2011-04-13 Medicago Inc. Influenza virus-like particles (vlps) comprising hemagglutinin
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
US20110182938A1 (en) * 2010-01-26 2011-07-28 Weiner David B Influenza nucleic acid molecules and vaccines made therefrom

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809237C2 (ru) * 2018-06-27 2023-12-08 Медикаго Инк. Мутанты гемагглютинина вируса гриппа

Also Published As

Publication number Publication date
IN2014DN05805A (enExample) 2015-05-15
JP2015506705A (ja) 2015-03-05
RU2018113521A (ru) 2019-03-04
EP2812348A4 (en) 2015-12-30
MX2014009148A (es) 2014-09-22
KR20140127827A (ko) 2014-11-04
AU2013217166B2 (en) 2017-04-06
US20150044247A1 (en) 2015-02-12
CN104136456A (zh) 2014-11-05
CA2863981A1 (en) 2013-08-15
SG11201404653UA (en) 2014-09-26
HK1203524A1 (en) 2015-10-30
US9234008B2 (en) 2016-01-12
AU2013217166A1 (en) 2014-08-28
BR112014018884A2 (pt) 2017-07-04
WO2013119683A1 (en) 2013-08-15
JP6336915B2 (ja) 2018-06-06
RU2014135703A (ru) 2016-03-27
AU2017204454A1 (en) 2017-07-20
EP2812348A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
RU2612900C2 (ru) Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
RU2653756C2 (ru) Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
RU2639551C2 (ru) Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
US10865228B2 (en) Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
JP2018183149A (ja) Ｈ１ｎ１インフルエンザに対する計算で最適化した広い反応性を示す抗原
HK1203523B (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
HK1197685A (en) Computationally optimized broadly reactive antigens for h1n1 influenza
HK1197685B (en) Computationally optimized broadly reactive antigens for h1n1 influenza

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200207